Recent developments in the use of chemotherapy in brain tumours

被引:119
作者
van den Bent, MJ
Hegi, ME
Stupp, R
机构
[1] Erasme Univ Hosp, Dr Daniel Den Hoed Canc Ctr, Dept Neurooncol, NL-3008 AE Rotterdam, Netherlands
[2] Univ Lausanne Hosp, Dept Neurosurg, Lab Tumor Biol & Genet, Lausanne, Switzerland
[3] Univ Lausanne Hosp, Multidisciplinary Oncol Ctr, Lausanne, Switzerland
关键词
glioblastoma; oligodendroglioma; anaplastic glioma; temozolomide; radiotherapy; PCV; MGMT;
D O I
10.1016/j.ejca.2005.06.031
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several recent studies have further clarified the role of chemotherapy in newly diagnosed anaplastic glioma. For newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolomide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase; this observation however, needs confirmation. Although oligodendroglial tumours are sensitive to chemotherapy, classical adjuvant nitrosourea-based chemotherapy does not improve overall survival in newly diagnosed anaplastic oligodendroglioma, even in the subset of 1p/19q loss tumours. It may increase progression-free survival however, and further studies must show if combined modality treatment with daily chemotherapy during radiotherapy increases survival. Trials exploring the role of chemotherapy in low-grade glioma are ongoing. No standard chemotherapy is currently available for highly anaplastic glioma failing first-line temozolomide-based therapy. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:582 / 588
页数:7
相关论文
共 63 条
[51]   Selective CD4+ lymphopenia in melanoma patients treated with temozolomide:: A toxicity with therapeutic implications [J].
Su, YB ;
Sohn, S ;
Krown, SE ;
Livingston, PO ;
Wolchok, JD ;
Quinn, C ;
Williams, L ;
Foster, T ;
Sepkowitz, KA ;
Chapman, PB .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (04) :610-616
[52]   Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules [J].
Tolcher, AW ;
Gerson, SL ;
Denis, L ;
Geyer, C ;
Hammond, LA ;
Patnaik, A ;
Goetz, AD ;
Schwartz, G ;
Edwards, T ;
Reyderman, L ;
Statkevich, P ;
Cutler, DL ;
Rowinsky, EK .
BRITISH JOURNAL OF CANCER, 2003, 88 (07) :1004-1011
[53]   Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas [J].
Triebels, VHJM ;
Taphoorn, MJB ;
Brandes, AA ;
Menten, J ;
Frenay, M ;
Tosoni, A ;
Kros, JM ;
Biemond-ter Stege, E ;
Enting, RH ;
Allgeier, A ;
van Heuvel, I ;
van den Bent, MJ .
NEUROLOGY, 2004, 63 (05) :904-906
[54]   Response rate and prognostic factors of recurrent oligodendroglioma treated with procarbazine, CCNU, and vincristine chemotherapy [J].
van den Bent, MJ ;
Kros, JM ;
Heimans, JJ ;
Pronk, LC ;
van Groeningen, CJ ;
Krouwer, HGJ ;
Taphoorn, MJB ;
Zonnenberg, BA ;
Tijssen, CC ;
Twijnstra, A ;
Punt, CJA ;
Boogerd, W .
NEUROLOGY, 1998, 51 (04) :1140-1145
[55]   Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 [J].
van den Bent, MJ ;
Chinot, O ;
Boogerd, W ;
Marques, JB ;
Taphoorn, MJB ;
Kros, JM ;
van der Rijt, CCD ;
Vecht, CJ ;
De Beule, N ;
Baron, B .
ANNALS OF ONCOLOGY, 2003, 14 (04) :599-602
[56]   Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971 [J].
van den Bent, MJ ;
Taphoorn, MJB ;
Brandes, AA ;
Menten, J ;
Stupp, R ;
Frenay, M ;
Chinot, O ;
Kros, JM ;
van der Rijt, CCD ;
Vecht, CJ ;
Allgeier, A ;
Gorlia, T .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2525-2528
[57]   Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features [J].
van den Bent, MJ ;
Looijenga, LHJ ;
Langenberg, K ;
Dinjens, W ;
Graveland, W ;
Uytdewilligen, L ;
Smitt, PAS ;
Jenkins, RB ;
Kros, JM .
CANCER, 2003, 97 (05) :1276-1284
[58]   Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors [J].
Vera, K ;
Djafari, L ;
Faivre, S ;
Guillamo, JS ;
Djazouli, K ;
Osorio, M ;
Parker, F ;
Cioloca, C ;
Abdulkarim, B ;
Armand, JP ;
Raymond, E .
ANNALS OF ONCOLOGY, 2004, 15 (01) :161-171
[59]   EVALUATION OF BCNU AND-OR RADIOTHERAPY IN TREATMENT OF ANAPLASTIC GLIOMAS - COOPERATIVE CLINICAL-TRIAL [J].
WALKER, MD ;
HUNT, WE ;
MAHALEY, MS ;
NORRELL, HA ;
RANSOHOFF, J ;
GEHAN, EA .
JOURNAL OF NEUROSURGERY, 1978, 49 (03) :333-343
[60]   RANDOMIZED COMPARISONS OF RADIOTHERAPY AND NITROSOUREAS FOR THE TREATMENT OF MALIGNANT GLIOMA AFTER SURGERY [J].
WALKER, MD ;
GREEN, SB ;
BYAR, DP ;
ALEXANDER, E ;
BATZDORF, U ;
BROOKS, WH ;
HUNT, WE ;
MACCARTY, CS ;
MAHALEY, MS ;
MEALEY, J ;
OWENS, G ;
RANSOHOFF, J ;
ROBERTSON, JT ;
SHAPIRO, WR ;
SMITH, KR ;
WILSON, CB ;
STRIKE, TA .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (23) :1323-1329